← Back to Search

Behavioural Intervention

Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence

N/A
Waitlist Available
Research Sponsored by Pear Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from week 1 to week 4
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new digital therapy to help people start and stick with buprenorphine treatment for opioid addiction.

Eligible Conditions
  • Opioid Use Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from week 1 to week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and from week 1 to week 4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Buprenorphine Initiation Success
Medication Adherence Rates
PEAR-002B Qualitative User Experience Interviews
+1 more
Secondary study objectives
PEAR-002B Engagement Data
reSET-O Qualitative User Experience Interviews
reSET-O User Satisfaction Surveys
Other study objectives
Abstinence From Illicit Opioids
Device Wearing Time
Physiological Biomarker Data
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PEAR-002B / reSET-OExperimental Treatment2 Interventions
Digital Therapeutic
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PEAR-002B
2022
N/A
~10
reSET-O
2022
N/A
~60

Find a Location

Who is running the clinical trial?

Whitman-Walker Institute, Inc.OTHER_GOV
Hassman Research Institute, LLCUNKNOWN
Pear Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
1,850 Total Patients Enrolled
Kaiser Foundation Research InstituteOTHER
27 Previous Clinical Trials
21,289 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,607 Previous Clinical Trials
3,329,808 Total Patients Enrolled
Christopher CannonStudy DirectorWhitman-Walker Institute, Inc.
Michael HassmanStudy DirectorHassman Research Institute, LLC
1 Previous Clinical Trials
17 Total Patients Enrolled
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top